Bright Minds Biosciences Inc. (TSE:DRUG) has released an update.
Bright Minds Biosciences Inc., a trailblazer in creating innovative treatments for neuropsychiatric diseases, epilepsy, and pain, announced the successful completion of its annual general meeting, where shareholders approved all agenda items, including the election of five directors and the appointment of DeVisser Gray LLP as auditors. Additionally, the company granted 130,000 stock options to directors and an employee, with each option being exercisable at $1.84 per share for five years. Bright Minds continues to advance its portfolio of next-generation serotonin agonists aimed at addressing hard-to-treat disorders.
For further insights into TSE:DRUG stock, check out TipRanks’ Stock Analysis page.
